Happy to share this paper from one of our #Swiss residents @PeterMacCC: Does IO given in #SCLC up front impact responses and survival in subsequent lines of therapy? Sadly the answer was no, chemo outcomes were similar to that seen pre-IO. Maybe BiTES? authors.elsevier.com/c/1lw8qcYZOi...

Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025

So much fun rehearsing some acoustic tunes with @drsanjaypopat.bsky.social - don’t forget to stick around after the #WCLC25 plenary tomorrow evening @iaslc.bsky.social

Looking forward to playing some tunes with my good friend and musician @drsanjaypopat.bsky.social tomorrow at #WCLC25. Make sure you stick around at the welcome reception Saturday evening!

Loving this @mayhemtomi track, a lovely collaboration with @dean_fennell on synths. Inspired by the “Pale blue dot speech” from Carl Sagan. Check it out on all streaming platforms details here: mayhemtom.com.au

🙏🏽 ABC for shining the light on 🇦🇺 deadliest cancer. Bring on #lungcancer screening www.abc.net.au/news/2025-06... @abcnewsbot.bsky.social @gerryhanna.bsky.social @drtomjohn.bsky.social @dkarikios.bsky.social @bensolomon1.bsky.social

🇦🇺 guidelines for #lungcancer screening. Screening coming 1st July. Great step forward in #lungcancer Mx. Spread the word. www.health.gov.au/our-work/nlc... @newsgp.bsky.social @ausgov.bsky.social @drtomjohn.bsky.social @bensolomon1.bsky.social @dkarikios.bsky.social

If you’re interested in where #lungcancer vaccines are at relative to #melanoma, check out this @togaanz.bsky.social podcast with @gvlongphdmd.bsky.social and Ken OByrne. podcasts.apple.com/au/podcast/v... open.spotify.com/episode/0OJb...

Australia completely lacks a dedicated training program for clinician scientists. With the vision and support of VMIAL @petermaccc.bsky.social is extremely proud to announce the first clinician-scientist fellowship. If you meet the eligibility criteria PLEASE APPLY! www.nature.com/naturecareer...

Close to releasing first single from new album. If you’re interested please presave it. Presaves help the #spotifyaunz and #applemusic algorithm figure out how hot a #indie #indiemusic track might be. gyro.to/Atheistic

🔥 @natmedicine.bsky.social 🆙 ✅Molecular residual disease analysis of adj osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC 🎯MRD preceded imaging DFS by a median of 4.7 🩸RaDaR MRD analysis 👥 Dr. Roy Herbst @drtomjohn.bsky.social #LCSM @oncoalert.bsky.social www.nature.com/articles/s41...

Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...

Great day for lung cancer care!. Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! Just a press release for now but full data upcoming! #lcsm news.bms.com/news/corpora...

Non KRAS G12C mutations an important unmet need in lung cancer: we see them often, including in non-smokers Nice work here highlighted by @drtomjohn.bsky.social We hope to open 1L RMC-6236 trial at Chelsea & Westminster later this year

Congratulations to Adel from @petermac for this analysis showing KRAS G12D patients are more likely to be non-smokers but also associated with low PDL1, comutations with TP53/STK11 and derive limited immunotherapy response. Area of need for targeted Rx #LCSM smex-ctp.trendmicro.com/wis/clicktim...

*New Publication* led by Dr Adel Shahnam from @petermaccc.bsky.social in Lung Cancer Poorer survival outcomes in patients with KRAS G12D mutations receiving immunotherapy. Novel targeted therapies should be examined in detail for this population. www.lungcancerjournal.info/article/S016... #lcsm

Lovely day at the #pinktest #mcgrath day in #sydney, India vs Australia.

HIT IT WITH YOUR BEST SHOT 👊 Catch our latest podcast on IO in early-stage NSCLC in the Australian context. Apple: https://buff.ly/3ZgBePP Spotify: https://buff.ly/3Ze0I0c

Lung cancer is the leading cause of cancer death in women. Don't ignore the signs! Thanks for coming on the journey with us this #LungCancerAwarenessMonth Find out more > https://buff.ly/3YG2OWB #LCAM

Time is running out to join us for the Kosi Climb with Prof Nick Pavlakis! Together, we can make an impact. Don't miss your chance to make a difference and be part of something special! Registrations close soon. Find out more > https://buff.ly/3Tov4LA

Having trouble thinking of a Christmas gift for someone? Go to ChatGPT and type in a summary of the person, a price range, and ask for gift ideas. List (with links) will follow. Tell others to do this for the gifts you will receive. Let’s (let AI) raise the standard of gift giving this Xmas!

Excellent summary from @donnadlubsky.social I really think we should be taxing these industries more. The amount of money wasted on supplements could be used to help fund trials and treatments that are proven to work. www.theguardian.com/commentisfre...

KEAP1-NRF2 pathway and expression of antioxidant genes, H/T: @angelifriedmann.bsky.social

With every new #lungcancer research finding, we move the needle for those impacted. It's why Dr @gerryhanna.bsky.social believes that LC research is improving care for patients in real time – we’re shifting the dial! Let's continue this. #BecauseofResearch #LCAM @younglungcancer.bsky.social

Always wonderful to be part of the #TOGAPreceptorship going through the main papers that determine how we treat #NSCLC today. Excellent presentations and discussions. But the best part is catching up with good mates! The future of thoracic oncology is bright 🌟

@oncoalert.bsky.social Starter pack Easy 👉🏼one click & followed all go.bsky.app/GKXp9Fy

#LungCancer survival rates rose 22% from 2015 to 2019. While promising, we want to see those numbers go much higher…while we're at it, let's shoot for 10, 15, 20 or more years. Learn how you can make an impact this Lung Cancer Awareness Month: buff.ly/4eDVXTo. #LCAM2024

Sharing a fledgling #LCSM starter pack for those joining Bluesky 🦋 #Medsky #Oncsky @oncoalert.bsky.social go.bsky.app/MjDxbG2

Where have all the doctors gone? www.medpagetoday.com/special-repo.... #digitalintervention #socialsky

'TrialGPT' A new chatGPT for clinical trials @natureportfolio.bsky.social: - 3 steps: TrialGPT-Retrieval, TrialGPT-Matching, TrialGPT-Ranking - Retrieval identified 90% suitable trials - 42% time-saving in matching a patient to a trial Like, wow #MedSky #OncSky #LCSM www.nature.com/articles/s41...

Hey @bsky.app can you do something about following people back? Current system is slow and clunky!

Warm night at St Paul’s cathedral Bendigo last night, playing with @lindamileshkin . Lovely acoustics, no mics, some amazing singers and instrumentalists. Thanks for having me @bendigo_health #melbournemusic #indiemusic #livemusic

Thank you Lisa, this now proudly sits on my desk. I think the person who really made the difference was you though. 🙏🏾😍💪🏾 #LCSM

In #lungcancer living 10 years with metastatic disease is testament to research and novel TKIs. So much has changed in that time and very grateful to be able to share this moment with Lisa, my colleagues and her personalised Lego figures! #LCSM

Guardian will no longer post on ‘X’. The exodus is gathering pace….

This is a great way to get your #Bluesky oncology #medtwitter started. Just hit follow all in top right corner…..

Very appropriate that people are moving to @bsky.app given the dumpster fire that #twitterx appears to become. Let’s do this! www.theguardian.com/technology/2...

Well here goes....hoping this is the new Twitter/X. Twitter/X is still a great way of disseminating medical information, but having to see its Musk's tweets constantly amongst other hate speech is a reason to leave. Here's to #bluesky thinking.....